Dear All: You are doubtless now familiar with all the reasons why we need pull incentives for AMR-related products (as background, see this blog). We don’t yet have anything beyond the US GAIN act and it alone will not suffice. In the US, there are discussions this week in the House of Representatives on reauthorizing PAHPA, the
Dear All: Late last year, I had the opportunity to hear a presentation on antibiotic R&D in Japan by Norio Ohmagari. Based in Tokyo at the National Center for Global Health and Medicine Hospital (link), Norio is Director of its (i) AMR Clinical Reference Center, (ii) Disease Control and Prevention Center, and (iii) WHO Collaborating
Dear All: Three important documents were released at / during / around the World Economic Forum meeting that occurred this week in Davos. First and foremost, we have the final report from DRIVE-AB. It’s a substantial document and you’ll need to set aside an afternoon to read it. As a way to get started, my 11 Sep 2017
Aside: Please look closely at the forward calendar. In addition to two new webinars from GARDP’s REVIVE project, there is a meeting in Thailand in December that focuses on alternatives to antibiotics. I’m told that the program is primarily focused on veterinary and agricultural uses, but previous year’s attendees have found the discussion to have broad application
Dear All: It was a HUGE day at the Pew Charitable Trusts today! First, Commissioner Scott Gottleib gave a superb and very exciting speech. You can either read or listen to the entire speech. There is also a panel discussion after his talk that is worth replaying. Here are some highlights from Commissioner Gottleib’s talk: FDA is working to coordinate
Dear All: For your weekend reading list, I have some papers on the topic of (mostly pull) incentives for antibiotics. First, I previously wrote about the survey from TATFAR (Transatlantic Task Force on Antimicrobial Resistance) of 6 possible pull models (higher reimbursement, diagnostic confirmation, market entry rewards both fully and partially delinked, tradable exclusivity vouchers, and an options market).
Dear All: I’ve written a lot about the need for pull incentives, preferably delinked (some papers to read, comments by TATFAR, highlights from Davos 2018, and the UK commits to trying delinkage). Now, I am delighted to report that a really serious effort is underway in the US to make something happen during the 116th Congress. The essential document can be
Dear All: We can’t say it too often … our current approach to buying antibiotics is broken in that it is tantamount to paying the firemen on a per-fire basis. We simply must change this! Driving this change requires persistent effort on the part of many. Over the past few days we’ve had two welcome additions to
Dear All: The TATFAR group has a new and very helpful paper out in Clinical Infectious Diseases in which they analyze 6 different kinds of pull incentives: Higher reimbursement Diagnosis confirmation (lower cost for a few days of empiric therapy, higher cost if diagnostics confirm ongoing need) A fully delinked market entry reward (no sales-based income) A